Our primary goal is creating new medicines for patients who need them. The first step toward that goal is understanding patient needs, perspectives and expectations. We engage patients and patient advocacy groups from the beginning of our development process to inform how we develop genomic medicines and design clinical trials that will best meet patient needs.
Our primary goal is creating new medicines for patients who need them. The first step toward that goal is understanding patient needs, perspectives and expectations. We engage patients and patient advocacy groups from the beginning of our development process to inform how we develop genomic medicines and design clinical trials that will best meet patient needs.
At Sangamo, patients are at the heart of our mission to translate ground-breaking science into medicines that transform their lives. Visit our dedicated Patient Stories page to learn more about their journeys.
At Sangamo, we are committed to offering patients valuable information to support them along their journey. Explore our Patient Resources page for educational materials and a list of organizations that can help guide you.
Expanded Access to Therapies in Development is a critical program that provides access to investigational drugs and therapies for patients facing life-threatening or serious medical conditions without approved treatment options. Learn more about the purpose and significance of these programs and their role in offering hope and improved outcomes to those in need.
— Sandy Macrae, Chief Executive Officer, Sangamo“Genomic medicine is a source of vast medical promise and new hope for patients. As a pioneer in genomic medicine, we believe we have an obligation to patients and society to help define the bioethical framework to guide this new field of medicine.”